Signal Genetics™ Receives Positive Coverage Decision and In-Network Provider Status from Arkansas Blue Cross Blue Shield for Its MyPRS™ Molecular Assay for Multiple Myeloma

Share Article

Accurate Prognosis and Molecular Subtyping is a Foundation of Personalized Medicine for Multiple Myeloma Patients

Signal Genetics

We are pleased that Arkansas Blue Cross Blue Shield is following Medicare and recognizing the value of the MyPRS™ test in the management of Multiple Myeloma.This announcement is part of our efforts to work with payers across the country.

Signal Genetics LLC, a leading provider of molecular assays for Multiple Myeloma, has received a positive coverage decision and in-network provider status from Arkansas Blue Cross Blue Shield for its MyPRS™ gene expression profiling assay. Little Rock-based Arkansas Blue Cross Blue Shield is part of the Blue Cross Blue Shield network, which serves more than 1 million members across the nation.

MyPRS™ is a molecular cancer assay performed on isolated plasma cells from a patient’s bone marrow. Genomic profiling of these cells results in a personalized prognostic score and molecular subtype that predicts outcome in patients with newly diagnosed or relapsed Multiple Myeloma. Extensive clinical trials and international peer-reviewed studies have been completed that reinforce the clinical validity and utility and prognostic performance of the test.

Sam Riccitelli, President and CEO of Signal Genetics, said, “We are pleased that Arkansas Blue Cross Blue Shield is following Medicare and recognizing the value of the MyPRS™ test in the management of Multiple Myeloma. With Multiple Myeloma, achieving prognostic certainty is critical to optimize therapies and ultimately, patient outcome. This announcement is part of our efforts to work with payers across the country to make this important prognostic test available to clinicians and their patients, helping to support personalized medicine with the goal of improving outcomes.”

MyPRS™ is becoming a standard tool in the management of Multiple Myeloma. More than 20,000 patients are diagnosed with Multiple Myeloma in the United States each year. An accurate assessment of each patients’ prognosis and molecular/cytogenetic characteristics is the first step toward personalized medicine, allowing clinicians managing these patients to treat them most effectively using current therapies.

---

About Arkansas Blue Cross Blue Shield

Founded in 1948, Arkansas Blue Cross and Blue Shield, an Independent Licensee of the Blue Cross and Blue Shield Association, is the largest health insurer in Arkansas. Arkansas Blue Cross and its family of affiliated companies have more than 2,500 employees.

Arkansas Blue Cross Blue Shield is a nonprofit organization nationally recognized for its commitment to providing innovative, high-quality healthcare coverage. The plan offers members and employers an array of health management programs, which support evidence-based approaches to health and wellness.

About Signal Genetics

Signal Genetics™ is an emerging commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer.

The company was founded in April 2010 after becoming the exclusive licensee to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences (UAMS). Signal Genetics’ flagship product - MyPRS™ (Myeloma Prognostic Risk Signature) is based upon more than two decades of clinical research on nearly 10,000 MM patients who received their care at UAMS.

Signal Genetics™ offer the MyPRS™ test out of its state-of-the-art, CLIA certified reference laboratory located in Little Rock, AR. The company is dedicated to making its extensively validated diagnostic services available to all patients who need them.

About MyPRS™

MyPRS™, developed by UAMS, has been marketed by Signal Genetics since 2011. The multi-gene test, performed on bone marrow aspirate material, has been incorporated into the routine management of patients diagnosed with Multiple Myeloma in numerous treatment centers across the country. MyPRS™ can be used at the time of initial myeloma diagnosis or if the patient has experienced a relapse of their disease.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sam Riccitelli
Visit website